Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems

Human castration-resistant prostate cancer (CRPC) is a significant target of clinical research. The use of DNA-damaging agents has a long history in cancer chemotherapy but is limited by their toxicities. The combination with a safer drug can be a strategy in reducing dosage and toxicity while incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Jo-Fan, Hsu, Jui-Ling, Sheng, Yi-Hua, Leu, Wohn-Jenn, Yu, Chia-Chun, Chan, She-Hung, Chan, Mei-Ling, Hsu, Lih-Ching, Liu, Shih-Ping, Guh, Jih-Hwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344441/
https://www.ncbi.nlm.nih.gov/pubmed/30705876
http://dx.doi.org/10.3389/fonc.2018.00681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344441/
https://www.ncbi.nlm.nih.gov/pubmed/30705876
http://dx.doi.org/10.3389/fonc.2018.00681

Ejemplares similares